- Home
- FORA vs MRSN Comparison
FORA vs MRSN Comparison
Compare FORA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- MRSN
- Stock Information
- Founded
- FORA 2014
- MRSN 2001
- Country
- FORA United States
- MRSN United States
- Employees
- FORA N/A
- MRSN N/A
- Industry
- FORA Computer Software: Prepackaged Software
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- MRSN Health Care
- Exchange
- FORA Nasdaq
- MRSN Nasdaq
- Market Cap
- FORA 77.6M
- MRSN 71.9M
- IPO Year
- FORA N/A
- MRSN 2017
- Fundamental
- Price
- FORA $2.41
- MRSN $0.53
- Analyst Decision
- FORA Strong Buy
- MRSN Buy
- Analyst Count
- FORA 1
- MRSN 7
- Target Price
- FORA $5.00
- MRSN $6.00
- AVG Volume (30 Days)
- FORA 57.0K
- MRSN 5.4M
- Earning Date
- FORA 03-27-2025
- MRSN 03-07-2025
- Dividend Yield
- FORA N/A
- MRSN N/A
- EPS Growth
- FORA N/A
- MRSN N/A
- EPS
- FORA N/A
- MRSN N/A
- Revenue
- FORA $19,709,723.00
- MRSN $34,837,000.00
- Revenue This Year
- FORA N/A
- MRSN N/A
- Revenue Next Year
- FORA $13.59
- MRSN N/A
- P/E Ratio
- FORA N/A
- MRSN N/A
- Revenue Growth
- FORA N/A
- MRSN N/A
- 52 Week Low
- FORA $1.96
- MRSN $0.49
- 52 Week High
- FORA $4.15
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- FORA 48.34
- MRSN 32.86
- Support Level
- FORA $2.35
- MRSN $0.56
- Resistance Level
- FORA $4.03
- MRSN $0.82
- Average True Range (ATR)
- FORA 0.45
- MRSN 0.07
- MACD
- FORA -0.01
- MRSN 0.03
- Stochastic Oscillator
- FORA 19.00
- MRSN 8.39
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.